Emibetuzumab

Drug Profile

Emibetuzumab

Alternative Names: c-MET monoclonal antibody - Eli Lilly; cMET antibody - Eli Lilly; LA-480; LY-2875358

Latest Information Update: 24 May 2017

Price : $50

At a glance

  • Originator Eli Lilly
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Proto oncogene protein c met inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Gastric cancer; Non-small cell lung cancer
  • Phase I/II Cancer

Most Recent Events

  • 05 Apr 2017 Safety and efficacy data from a phase I/II trial in Cancer presented at 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
  • 01 Apr 2017 Pharmacodynamics data from preclinical studies in Cancer presented at 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
  • 26 Oct 2016 Eli Lilly and Company completes a phase I trial in Cancer (Late-stage disease, Combination therapy) in USA (NCT01287546)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top